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ABSTRACT 
Aims: The objective of this thesis is to examine the relationship between suicide and health care 
in Italy’s Friuli Venezia Giulia (FVG) region. First, it explores the correlation between suicide 
rates and antidepressant sales. Second, it analyses, at the individual level, the risk of suicide 
associated with the main suicidal risk factors, such as non-fatal self-harm, psychiatric disorders 
and somatic disorders. Third, it investigates the differences in suicide risk related to qualitative 
parameters in the use of antidepressants, such as adherence and treatment modifications. The 
overall aim is to help improve interventions to prevent suicide. 
Methods: All data were retrieved from the FVG Regional Social and Health Information 
System (SISSR), which links data using a unique anonymous key from different regional 
databases. Paper I analyses changes in individual-based data on antidepressant use and the 
rates of suicide during years 1997-2006. The other three papers are designed as case-control 
studies. All suicides that occurred in the region during years 2002-2008 (Paper II) and 2003-
2013 (Paper III) were classified as cases, which were then age- and gender- matched to 
controls from the general population. In Paper IV, cases and controls from 2005 to 2014 must 
have had at least one prescription of antidepressant in the 730 days prior to the index date. 
Regression analysis was used to assess the association between suicide risk and its predictors. 
Results: In Paper I, suicide rates decreased by one-third in all genders and age groups. In 
parallel, both the number of individual users of antidepressant and the number of Defined Daily 
Doses per patient increased by 5-fold and 7-fold, respectively. In Paper II, the risk of suicide 
was highly increased by previous self-harm (OR = 53.1 for a single episode and OR = 98. for 
repeated episodes), as by psychiatric disorders (OR = 19.5). In Paper III, somatic disorders were 
strong predictors of suicide (OR = 2.9), particularly in case of comorbid disorders (OR from 2.6 
to 9.8 when the number of disorders raised from 1 to  ≥4) and in the elderly (OR = 4.3). No 
significant risk of suicide was found when medically-ill patients adhere to antidepressants. In 
Paper IV, none of the antidepressants compounds and classes was associated to suicide except 
SSRI (OR = 1.6). The association to suicide tended to decrease with adherence or current use of 
antidepressants. In all studies, on average only 10-20% of suicide cases adhere to 
antidepressants and 20-40% were currently using them at the time of death. 
Conclusions: Our findings support the hypothesis that treatment with antidepressant medication 
lowers the risk of suicide. The treatment at a proper dosage and for a proper length of time 
further decreased the risk, particularly in somatic-ill persons. Well-known risk factors, such as 
non-fatal self-harm and psychiatric and somatic disorders, were confirmed to highly increase 
the risk of suicide. Only a minority of suicides, however, had adhered to antidepressants or were 
under antidepressant treatment at the time of death.  
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1 BACKGROUND 
The pain and suffering behind every suicide are the reasons why Jamison KR in the book 
Night falls fast: understanding suicide, describes it as “a tragedy”. When I decided to become 
a psychiatrist, I did not know what the implications of suicide were. The first suicide I had to 
face was shocking. He was a medical student, around my age, whom I had known for a long 
time. The pain of his parents and friends was heart-breaking. I was hurt too, but I had to react. 
I also had to react in all the following deaths by suicide I had to face afterwards. My research 
on suicide gave me a chance to explore my feelings on the matter. A desire to understand 
suicide and hopefully contribute to its prevention has driven my work during these PhD years. 
I am also confident this will occur in my future career. 
As recently stated by the World Health Organization (WHO), suicide prevention is “a global 
imperative”(1). Globally, at least 800,000 individuals voluntarily die every year, but the 
number is certainly much higher. Registration of suicide deaths is a challenging issue in many 
countries, due to cultural and religious beliefs and consequent stigmatization. In some 
countries suicidal behaviours are even illegal. Suicide registration is also complicated, since it 
is a multilevel procedure that includes medical and legal concerns involving several 
responsible authorities. Worldwide, however, suicide is included among the main causes of 
death, particularly in young adults, making it a major public health problem (1).  
What should be done to help prevent as many as possible of these deaths? Prevention 
strategies at the population level include the enforcement of mental health and alcohol use 
policies, improved access to health services, restricted access to the means of suicide (such as 
firearms), the promotion of responsible media reporting and increased awareness about 
mental health, substance use disorders and suicide. The efficacy of these strategies, however, 
is difficult to assess. Suicide prevention strategies at the individual level are usually directed 
at subjects with a greater suicidal risk. The main risk factors of suicidal behaviours are well 
identified and include previous suicide attempts, mental disorders, harmful use of alcohol, 
chronic somatic conditions and other factors, such as job or financial loss, family history of 
suicide, genetic and biological factors. Nonetheless, the majority of suicide victims suffer 
mental disorders (1, 2). Among these disorders, depressive disorders are highly prevalent in 
the general population (3, 4), and are observed to a great extent in suicide deaths (5). Studies 
have shown that only a minority of suicide victims receive adequate pharmacological 
treatment with available medications, such as antidepressants (6). On the other hand, many 
ecological studies in recent years have observed a decrease in suicide rates that parallels an 
increase in sales of antidepressants (7-9). Although these studies mainly consider high-income 
countries, thus preventing a definitive conclusion on a causal relationship, there is growing 
evidence that proper treatment of depression can be crucial for the prevention of many 
suicides. In spite of this clear correlation, few studies have analysed antidepressant use in 
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individual suicides. Fewer still have analysed the relationship between suicidal risk factors, 
such as psychiatric and somatic disorders, and antidepressant use. The assessment of 
qualitative parameters of antidepressant use prior to suicide seems also crucial. 
1.1 EPIDEMIOLOGY OF SUICIDE 
Globally, the total number of deaths by suicide is over 800 000 people annually, accounting for 
1-4% of deaths worldwide. Both demographic factors, such as gender and age groups, and 
geographical variations should be taken into account when studying suicidal behaviour. 
Suicide can occur at any point in a person’s life, yet takes a particularly large toll on youth. 
Worldwide, suicide is the second most frequent cause of death among young people aged 15–24 
years, though in some regions, such as South-East Asia, it is the leading cause of death in this 
age group. Suicide attempts are some 20 to 30 times more frequent than completed suicides.  
Globally, the total number of deaths by suicide is over 800 000 people annually, accounting 
for 1-4% of deaths worldwide. Both demographic factors, such as gender and age groups, and 
geographical variations should be taken into account when studying suicidal behaviour. 
Suicide can occur at any point in a person’s life, yet takes a particularly large toll on youth. 
Worldwide, suicide is the second most frequent cause of death among young people aged 15–
24 years, though in some regions, such as South-East Asia, it is the leading cause of death in 
this age group. Suicide attempts are some 20 to 30 times more frequent than completed 
suicides (1). 
Males are generally at higher risk of completed suicide, while females are at higher risk of 
suicide attempts (10). In high-income countries, the risk of completed suicide is three times 
higher in males than females, while in middle and low-income countries the risk is 1.5 times 
higher. Nevertheless, there are large differences between regions and between countries (1). 
Moreover, the risk of suicide usually increases with age. Suicide is extremely rare in children 
under 12 years old, but suicide incidence increases every year during and after puberty. The 
absolute and relative rate of suicide in people older than 60 years is higher compared to the 
general population. The proportion of suicides in older than 75 years is three times higher 
than in younger. Differences may be found among high-income and low income countries. As 
an example, high-income countries have greater suicidal rates among young adults and old 
women (1).  
Despite the significant public health problem that suicide poses worldwide, there is evidence 
to suggest that efforts to curb suicide deaths have met with some success. For example, 
between 2000 and 2012, the total number of suicides registered worldwide decreased by about 
9%, from 883,000 to 804,000, despite the increase of 13.4% in the global population in the 
same period. The global age-standardized suicide rate (which adjusts for differences in the 
size and age structure of populations over time) also decreased by 26% (23% in men and 32% 
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in women) during this 12-year period (1). The WHO has stated that the goal of reducing the 
2000 suicide rate by 10% by 2020 might be achievable if this trend can be maintained (11).  
1.1.1 The Region Friuli Venezia Giulia, Italy 
Italy is a densely populated country with close to 60 million inhabitants. Compared with most 
other European countries suicide rates are low (5.1 suicides per 100 000 inhabitants in 2010) 
(12).  
Friuli Venezia Giulia (FVG) is a region in the North-East of Italy with 1.2 million inhabitants. 
Although it had the highest suicide rate of the whole country in 1997 (15.7 suicides per 100,000 
inhabitants), a decrease in suicide rates has been observed in recent years (8.4 suicides per 
100,000 inhabitants in 2015). Over this nineteen-year period (1997-2015), a decrease in suicide 
rates in FVG has been observed also in both genders and all age groups with the greatest 
decrease observed in males and individuals over 60 years of age (fig. 1 and 2). Suicide rates in 
the region were three times higher in males than females (fig. 1), and in older age groups than 
younger (fig. 2), consistent with international findings (1, 10).  
The Epidemiological Register of FVG (the Regional Social and Health Information System 
(SISSR)), is the only health registry in Italy permitted to link administrative and healthcare data 
for an entire region. This enables the study of suicide and antidepressant use at both the 
population and individual level in FVG. 
 
Fig. 1: Suicide rate in males and females in Friuli Venezia Giulia 1997–2015  
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Fig. 2 Suicide rate in age groups 0-29; 30-59 and more than 60 years old in Friuli Venezia Giulia 1997–2015 
 
1.2 MAIN SUICIDAL RISK FACTORS 
Suicide is a complex phenomenon, since many factors at the individual and societal level may 
be implicated in suicidal behaviours. Suicide is usually explained as a convergence of genetic, 
psychological, social, and cultural risk factors, combined with experiences of trauma and loss 
(2). The WHO has divided suicidal risk factors into systemic, societal, community, relationship 
(social connectedness to immediate family and friends) and individual factors (1). Of these, 
individual factors have been more investigated and more scientific background information is 
available. The main individual suicidal risk factors are analysed in more detail below.  
1.2.1 Self-harm 
It is well established in the literature that the strongest risk factor for completed suicide is a 
previous history of deliberate self-harm (13). It is generally agreed that the likelihood of 
committing suicide after a self-harm episode increases 50 to 100 times, with 1 in 15 people 
dying by suicide within nine years of the self-harm episode (14). A recent study showed that for 
individuals who self-harmed, the risk of suicide was 131 times higher during the year 
following a self-harm act (15). The risk further increases in case of repeated self-harm episodes 
(16), especially in females (17).   
1.2.2 Psychiatric disorders 
Psychiatric disorders are also among the most consistently reported risk factors for suicidal 
behaviour (18). Psychological autopsy studies are the most frequent approach for investigating 
such associations (19). These have demonstrated that 90–95 % of suicide victims had been 
diagnosed with a psychiatric disorder prior to suicide (10, 20).  
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A recent review (21) confirmed the role of mental health and substance use disorders as major 
risk factors for suicide; in the countries considered, 84.5% of completed suicides were due to 
these disorders. Authors claimed that mental health and substance use disorders were also 
responsible of more than 60% of total suicide Disability Adjusted Life Years (DALYs), defined 
as years lost due to disease and disability. These disorders were therefore ranked as the third 
leading disease category of global health burden in 2010, with major depressive disorder having 
the largest health burden in this category. The attributable suicide DALYs was higher in males 
than females in most age groups, with the exception of females between 10 and 19 years old.  
Among psychiatric disorders, depressive and bipolar disorders (affective disorders) have been 
demonstrated to account for the highest suicide risk (10, 22). It has been reported that 9%–15% 
of deaths among persons with affective disorders are due to suicide, although the proportion 
may be as low as 4% among persons with mild affective disorders (23). The prevalence of 
depression among suicide victim is the highest, since more than 50% of all people who die by 
suicide meet criteria for depressive disorder at the time of death (19, 24-27).  
Other psychiatric disorders usually associated with a higher suicidal risk are psychotic 
disorders, personality disorders and alcohol use disorders. The lifetime risk of suicide in 
schizophrenia is about 4-5%, while the prevalence of personality disorders - particularly 
borderline and antisocial personality disorders - in suicide victims is around 30-40%. Many of 
these people, however, as well as the patients who previously had committed non-lethal self- 
harm, have also been shown to suffer from depressive symptoms prior to suicide (10). The 
lifetime risk of suicide in alcohol dependence is about 8% (28). People with eating disorders, in 
particular anorexia nervosa, are also at increased risk of suicide (10). 
While there is  no evidence that anxiety disorders alone lead to increased risk of suicide (29), 
when co-morbid with other mental disorders, anxiety has been shown to be a risk factor for 
suicide (30).  
1.2.3 Somatic disorders 
Somatic disorders, particularly cancer, may increase the risk of suicide (31-34).  A recent study 
from Denmark demonstrated an increased risk in all somatic diagnostic categories (35). Other 
studies found a higher risk of suicide in Chronic Obstructive Pulmonary Disease (COPD) (36), 
in stroke (37) and myocardial infarction (38), and in neurological disorders (31). Notably, 
underlying depressive symptoms had been shown by patients with a variety of somatic 
disorders, including cancer (39, 40), stroke (41, 42), neurological disorders (43-45), myocardial 
infarction (46, 47), gastrointestinal diseases (48), COPD (49), endocrine disorders (50) and 
musculoskeletal disorders (51). 
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1.2.4 Economic crisis 
Unemployment and financial loss may have a role in increasing suicidal risk, since these factors 
are associated with a higher burden of depression, anxiety and alcohol abuse (52). Economic 
crisis may therefore influence the individual risk of suicide, nowadays and in the past (53, 54). 
Nonetheless, a recent European review did not demonstrate a clear causal relationship between 
economic indices associated to the current economic crisis and an increase in the rates of 
suicide (55). 
1.2.5 Familiar history of suicide 
Suicidal behaviour is highly prevalent in families with a history of suicide, independent from 
the heredity of psychiatric disorders (56). Suicide risk, in fact, had been found to be twice as 
high in families of suicide victims as in comparable families (57). This may be related to both 
genetic dispositions as well as environmental factors (56). The negative impact of a suicide on a 
family can led to stress, shame, guilt, anger and anxiety. In consequence, family dynamics may 
change and support from others may be disrupted, due to stigma and hindered help-seeking (1).  
1.3 PHARMACOLOGICAL TREATMENT OF SUICIDES 
Suicide should be considered as a negative outcome of severe psychological suffering that can 
be mediated by the interactions of many factors. Consequently, it is not possible to identify a 
specific treatment for suicide. However, the proper pharmacological treatment of the underlying 
mental disorders may be a central component of suicide prevention strategies. Since mental 
disorders in most cases a probably necessary risk factor, its proper treatment may protect an 
individual from suicide. Moreover, psychiatric disorder is underlying many other suicidal risk 
factors.  
Lithium is the drug that the best proven antisuicidal effect (58). This effect has been 
demonstrated both in monotherapy, as well as in combination with antidepressant treatment 
(59). Clozapine has also been shown to play a role in suicide prevention in psychotic patients 
(60). Other antipsychotic or mood stabilizing drugs (61, 62), have no proven effect in 
preventing suicide.  
1.4  ANTIDEPRESSANT TREATMENT OF SUICIDES 
Studies have shown that more than half of suicide victims suffered from depression prior to 
death (19). Antidepressant medication is the basic acute treatment of depression. An 
improvement in the treatment of depression in the population therefore appears to be a logical 
intervention in suicide prevention (6).  
There is growing evidence worldwide, particularly from ecological studies, that antidepressants 
may play an important role in preventing suicidal behaviour (6-8, 63, 64). This evidence has 
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increased since the introduction of new antidepressant compounds, such as Selective Serotonin 
Reuptake Inhibitors (SSRI), that have fewer side-effects and a lower toxicity profile compared 
to older Tricyclic (TCA), possibly contributing to better patient compliance (65, 66). 
Nonetheless, there are official warnings that antidepressants might increase suicide risk in 
young subjects, particularly in the first months of treatmentas reported from meta-analyses of 
Randomized Clinical Trials (RCTs) (67). These findings, however, suffer from various 
limitations such as short study periods and the use of suicide ideation as a surrogate for suicide 
risk (67). Moreover, recent population-based studies failed to show such higher suicide risk (68-
72), Furthermore, there are worrying indications that the official warnings have been contra-
productive. From US came early signals that these warnings had led to a decrease in the use of 
antidepressants and an concomitant increase in young suicide (73). From Sweden was reported, 
from an individual-based controlled study, increasing rates of young (10-19 years) suicides in 
the five consecutive years from 2003(72). 
1.4.1  Ecological studies 
Evidence of an inverse correlation between suicide rates and antidepressant use has been 
cumulated from ecological studies since the first report by Isacsson in 2000, where he reported 
correlations of increases of antidepressant use and decreasing suicide rates 1978-1996 in 
Sweden, in Norway, Denmark, Finland 1990-1995 and USA from 1987 (64). Rihmer confirmed 
similar findings in Hungary 1984-1998 (74). In 2005, Ludwig & Marcotte (7) analysed data on 
suicide rates and antidepressant sales in 27 countries from 1980 to 2000. They demonstrated 
that an increase of one pill of antidepressant per capita (a 13% increase over 1999 levels) was 
associated with a 2.5% reduction in suicide rates. This relationship was more pronounced for 
adults than for children. In the same year, Isacsson & Rich (9) reviewed research from nine 
countries and found in most of them an inverse correlation between rising antidepressant use 
and falling suicide rates. In 2007, Baldessarini et al. (63) reviewed nineteen studies from 
different countries between 1980 and 2000. They found that suicide rates decreased by 14% 
overall while antidepressant prescriptions increased by an average of 395%. However the 
findings were heterogeneous, since only eight out of the nineteen selected studies found 
significant inverse correlations between rising sales of antidepressants after the introduction of 
SSRIs  in the 1990s and a decrease in suicide rates not anticipated in the 1980s. Nonetheless, 
Isacsson & Mathè (75) argued that only three studies, among the 19 reviewed by Baldessarini et 
al., did not find any inverse correlation. In fact, eleven studies were positive, and five studies 
found an inverse correlation among the elderly. Furthermore, all three negative studies derived 
from small countries with a very low number of suicides per year (Iceland, Northern Ireland, 
Slovenia).  
As summarized in Table 1, this inverse correlation was found in most of the countries where 
studies were published after year 2000. Data on antidepressant use and suicide rates were dated, 
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however, with no data available beyond 2006. The latest review conducted in 2013 (8),is based 
on data from 29 European countries between 1980 and 2009 and found that suicide rates tended 
to decrease more in countries where there had been a greater increase in the use of 
antidepressants, thus providing further evidence that the use of antidepressants has a positive 
effect on suicide prevention. 
 
Table 1: Selected ecological studies published after year 2000 on suicide rates and antidepressant use by country 
(all ages and gender are considered) 
Reference Country Period Suicide rates Antidepressant use 
Outcome  
(correlation) 
Isacsson  (2000) 
(64) 
Sweden 1978 - 1996 19% decrease 82% increase Positive 
Rihmer et al. 
(2001) (76) 
Hungary 1984-1998 30% decrease 83% increase Positive 
Oravecz et al. 
(2003) (77) 
Slovenia 1984-1997 7.1% increase 58% increase Negative 
Kelly et al. 
(2003) (78) 
Northern 
Ireland 
1989-1999 8% increase 467% increase 
Negative (more in 
the ≤30 age group) 
Hall et al. 
(2003) (79) 
Australia 1991-2000 
increase in 25-
44 age group 
decrease in  
>44 age group 
209% increase 
Positive (the age 
group with greater 
increase in 
antidepressants use 
tended to have 
greater decrease in 
suicide rates) 
Helgason et al. 
(2004) (80) 
Iceland 1950-2000 unchanged 388% increase Negative 
Morgan et al. 
(2004) (81) 
England 1993-2002 85.8% decrease 237.5% increase Positive 
Grunebaum et 
al. (2004) (82) 
US 1985-1999 13.5% decrease 413% increase Positive 
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Barak & 
Aizenberg 
(2006) (83) 
Israel 1998–2002 17.6% decrease  160% increase 
Positive, but 
significant only in 
men aged 55-74 
years  
Milane et al. 
(2006) (84) 
US 1988-2002 14.4% decrease 
1248% increase 
(Fluoxetine) 
Positive 
Reseland et al. 
(2006) (85) 
Sweden, 
Norway, 
Denmark, 
Finland 
1961-2003 33.6% decrease 410% increase Positive 
Nakagawa et al. 
(2007) (73) 
Japan 1999-2003 54% increase 56% increase 
Positive: inverse 
association between 
year-to-year changes 
in SSRI prescribing 
and suicide rates  
Bramness et al. 
(2007) (86) 
Norway 1980-2004 28% decrease 
100% increase (non-
Tricyclics) 
Positive 
Sebestyen et al. 
(2010) (87) 
Hungary 1998-2006 23% decrease 113% increase Positive 
1.4.1.1 Italian studies 
Two studies analysed the correlation between suicide rate and antidepressant prescriptions in 
Italy. The first (88) analysed data on suicide rates and antidepressant sales from 1988 to1996. 
Authors found a 53% increase in antidepressant sales, mainly due to the increasing use of  
SSRIs. During the same years, suicide rates slightly increased for men (from 9.8 to 10.2 per 
100,000 inhabitants) and decreased for women (from 3.9 to 3.2 per 100,000). The second study 
(89) analysed data on antidepressant sales from 1983 to 2000 and suicide rates from 1955 to 
2000. A 336% increase in antidepressant use was observed, while suicide rates decreased in the 
same period both in men (from 14.1 to 10.9) and women (from 5.4 to 3.5). In the over 65 age 
group the decrease was also consistent (25% in men and 33% in women), however data on 
antidepressant sales by age group were not available.  
A study from the Veneto region (90) of antidepressant prescriptions from 2000 to 2005 found a 
more pronounced increase in prescriptions in males and in people aged 65 and older. Suicide 
rates did not change in either gender over these years. Suicide rates by age group, however, 
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were not available. This data gap hindered more detailed analyses on the inverse correlation 
between suicide rates and antidepressant prescriptions.  
1.4.2 Population-based studies  
Few register-based studies analysed the use of antidepressants in suicides compared to controls 
from the general population at the individual level (Table 2). Six (71, 91-95) out of the seven 
cohort studies selected found a positive outcome with regard to a preventive effect of 
antidepressants on suicide risk. One cohort study (68) found no increased risk of suicide along 
with the current use of antidepressants compared to past use. However, this finding gives no 
information on the possible effect of current antidepressant treatment on suicide. Nonetheless, 
one case-control study (69) found that a longer treatment with antidepressants was associated 
with lower suicide risk. Another case-control study (96) failed to demonstrate a higher risk of 
suicide in antidepressant users compared to controls. Two studies (70, 97) compared the risk of 
suicide in SSRI users to TCA or other antidepressant users. They found low or no evidence of 
higher risk in SSRI users. Only one study (98) found no difference in suicide risk between 
subjects who discontinued antidepressant treatment compared with those who did not, thus 
excluding a preventive effect of antidepressants on suicide. The study, however, was limited to 
subjects older than 50 years.  
 
Table 2: Selected population-based studies published after year 2000 on the use of antidepressants in suicides 
compared to controls from the general population  
Reference Country Period 
Study 
design 
Study sample 
Age 
groups 
and 
gender 
Main results 
concerning the 
risk of suicide 
and AD use 
Outcome 
(preventing 
effect of AD 
on suicide) 
Jick et al. 
(2004) (69) 
UK 
1993-
1999 
Case-
control 
17 cases 
(suicides) who 
received AD 
within 90 days 
before death 
(index date) 
157 controls 
All (10 
to 69 
years 
old) 
Patients who 
started AD 
treatment within 1 
to 9 days prior to 
index date have an 
increased risk of 
suicide 38 times 
higher than those 
who started AD 
≥90 days prior to 
the index date 
Inconsistent, 
but longer 
treatment 
with AD 
associated to 
lower suicide 
risk 
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Didham et 
al. (2005) 
(96) 
New 
Zealand 
1996-
2001 
Nested 
case-
control 
26 cases 
(suicides) 
78 controls 
All 
No increased risk 
of suicide in AD 
users (SSRIs, 
TCAs) when 
adjusted for 
confounders (age, 
gender, 
depression/suicidal 
ideation)  
Inconsistent 
Martinez et 
al. (2005) 
(70) 
UK 
1995-
2001 
Nested 
case-
control 
69 cases 
(suicides) with 
a first 
prescription of 
AD for 
depression  
1121 controls 
All 
No evidence of 
increased risk in 
SSRIs users 
compared to TCAs 
users 
Inconsistent 
Tiihonen et 
al. (2006) 
(71) 
Finland 
1997-
2003 
Cohort 
15,390 
subjects 
hospitalized 
with a 
diagnosis of 
suicide 
attempt (602 
suicides) 
All 
No increased RR 
of suicide in TCA, 
SSRI and SNRI 
users 
Current use of AD 
was associated 
with decreased 
risk of suicide  
Positive 
Sondergard 
et al. (2006) 
(93) 
Denmark 
1995-
1999 
Cohort 
438,625 AD 
users 
compared to 
1,199,057 
controls (2144 
suicides) 
All ≥18 
years 
old 
Suicide rates 
decreased both in 
AD users and no 
AD users, but the 
decrease in suicide 
rates was more 
pronounced in AD 
users 
Positive 
Sondergard 
et al. (2006) 
(92) 
Denmark 
1995-
1999 
Cohort 
438,625 AD 
users 
compared to 
1,073,862 
controls (2145 
suicides) 
All ≥18 
years 
old 
Suicide rates 
decreased with the 
number of AD 
prescriptions and 
when patients 
purchased SSRIs 
and newer ADs 
Positive 
(continued 
treatment 
decreases 
suicide risk) 
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≥2-fold compared 
to patients who 
purchased once 
Simon et al. 
(2006) (97) 
US 
1992-
2003 
(June) 
Cohort 
65,103 AD 
users (31 
suicides in the 
6 months-
follow-up) 
All 
No significant 
increase in suicide 
risk after starting 
treatment with 
new AD compared 
to subsequent 
months 
Inconsistent, 
but did not 
demonstrate a 
higher risk in 
the first phase 
of treatment 
Juurlink et 
al. (99) 
Canada 
1992-
2000 
Case-
control 
1138 cases 
(suicides) 
4552 controls 
All ≥66 
years 
old 
Increased risk of 
suicide in the first 
month of therapy 
with SSRIs 
compared with 
other AD, but 
absolute risk is 
low and under 
treatment high 
(68%) 
Inconsistent 
Sondergard 
et al. (2007) 
Denmark 
1995-
2000 
Cohort 
31,422 
patients 
diagnosed 
with 
depression 
(310 suicides) 
All ≥18 
years 
old 
Suicide rates 
decreased with the 
number of AD 
prescriptions and 
when patients 
purchased ADs 
≥2-fold compared 
to patients who 
purchased once 
Positive 
(continued 
treatment 
decreases 
suicide risk) 
Haukka et 
al. (2009) 
(91) 
Finland 
1999-
2003 
Cohort 
258,417 AD 
users (886 
suicides) 
All 
Current AD use 
was not associated 
with lower risk of 
suicide compared 
to one-prescription 
group, with the 
exception of 
SSRIs users 
Positive only 
for SSRIs 
Erlangsen 
et al. (2009) 
Denmark 
1995-
2000 
Case-
control 
125,426  (323 
suicides) who 
not 
All ≥50 
years 
No difference in 
suicide risk 
between subjects 
Negative 
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(100) discontinued 
AD treatment 
91,089 (215 
suicides) who 
discontinued 
treatment early 
old who discontinued 
AD treatment 
compared to 
whom did not  
Leon et al. 
(2011) (95) 
US 
1979-
81 to 
2006-
09 
Cohort 
757 
participants 
with affective 
and 
schizoaffective 
diagnoses 
from 5 
medical 
centers (26 
suicides) 
All ≥17 
years 
old 
The risk of suicide 
decreased by 20% 
among AD users  
Positive 
Cheung et 
al. (2015) 
(68) 
Netherlands 
1994-
2012 
Cohort 
27,712 AD 
users (280 
suicides and 
suicide 
attempters) 
All 
Current use of AD 
(SSRIs, TCAs and 
other) did not 
increase suicide 
risk compared to 
past use of AD 
Inconsistent 
AD antidepressants; SSRI Selective Serotonin Reuptake Inhibitors; SNRI Serotoninergic Noradrenergic Reuptake 
Inhibitors; TCA Tricyclic  
1.4.3 Under-treatment with antidepressants 
Population-based studies observed an under-treatment with antidepressants in depressed 
individuals (101, 102), as well as poor adherence to antidepressant treatment, both in Italy (103, 
104), as well as in other countries (105-108). Moreover, a recent review (109) observed a strong 
association between non-adherence to antidepressants and a worsening of patients’ clinical 
outcomes, such as risk of relapse and recurrence of depressive episodes and consequent increase 
in symptom severity, decreased treatment response and remission, and a higher number of 
hospitalizations and visits to Emergency Departments. Economic outcomes, such as higher 
healthcare expenditures, have been also claimed.  
Few studies based on prescription registers analysed the use antidepressants in suicide victims. 
A study from Jamtland county, Sweden (110), found that only seven patients out of 59 (12%) 
who later committed suicide were dispensed antidepressants in the last 90 days before death. 
Another Swedish study found that 61 (20%) out of the 295 subjects aged 10 – 19 years who had 
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committed suicide between 2006 and 2010 had been prescribed an antidepressant in the six 
months prior to death. However, only 41 of them (14%) were compliant with their prescription, 
as indicated by the dispensation of more than one prescription (72). A study from Funen county, 
Denmark (111), found that 108 suicides out of 390 were dispensed antidepressants one year 
before death, but only 34 suicides (8.7%) received adequate treatment one month before death. 
A study from Ontario, Canada (97), found that 422 out of 1329 suicides (32%), aged 66 years 
and older, were dispensed antidepressants in the 6 months before death.  
Furthermore, studies that analysed treatment after non-fatal self-harm also indicated a low use 
of antidepressants. Suominen et al. (112) observed that only seven depressed patients out of 43 
(17%) received an adequate treatment with antidepressants during the month before and after a 
suicide attempt. Another study (113) found that the proportion of patients with a diagnosis of 
Major Depression exposed to antidepressant treatment was significantly lower in in the group of 
patients who had attempted suicide than a control group (42 vs 58%). 
1.4.3.1 Toxicological studies 
There is evidence from studies based on forensic toxicological screening of suicide victims that 
they have seldom been treated with antidepressants (114-116). In Sweden, Isacsson et al. found 
that the number of suicides exposed to antidepressants was 16% in 1999-91(116). In a 
subsequent study, the authors found that the number of suicide victims exposed to 
antidepressants had increased to 28.9% in 2005(6). Thus the detections of antidepressants had 
increased 2-fold, which was a remarkably small increase since the use of antidepressants had 
increased 8-fold in the population. In the study of young suicides, mentioned above, the average 
number of suicides aged 10 – 19 years in whom antidepressants were detected in toxicological 
screening was 1.7 out of 407 cases per year (0.4 %) from 1992–2002 and 7.4 out of 438 cases 
per year (1.7 %) from 2003–2010 (72). In a study from New York City, Leon et al. (117) 
observed that 23.1% of the 1419 adult suicides showed evidence of antidepressants in 
toxicology analyses from 2001 to 2004. These toxicological data should be seen in the light of 
that 50-80 % of the suicide victims were depressed (19, 24-27). 
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2 AIMS 
The overall aim of the thesis has been to explore the relation of suicide to health care in the 
FVG region, Italy, particularly with regard to appropriate pharmacological medication, such as 
antidepressants. More specifically, it explored the correlation between suicide rates and 
antidepressant sales, as well as the individual of risk level by the main suicidal risk factors, such 
as non-fatal self-harm, psychiatric disorders and somatic disorders. It further aimed to explore 
the differences in suicide risk related to qualitative parameters in the use of antidepressants, 
such as adherence and treatment modifications. By contributing to a better understanding of the 
relationship between suicide and health care, this thesis aimed to help improve interventions to 
prevent suicide, a major public health problem and among the most tragic.  
The specific aims for the included papers were: 
Paper I: To compare suicide trends and the use of antidepressants in the FVG region, using 
individual-based data on suicides and on the use of antidepressants. The hypothesis was that 
suicide rates decreased in parallel with an increasing trend in antidepressant prescriptions, as 
observed previously in several ecological studies. An under-treatment with antidepressants in 
the three months before death was also hypothesized. 
Paper II: To explore to what extent and under which diagnoses suicides had received 
psychiatric in-patient care, to explore to what extent they had previously committed non-lethal 
self-harm, and to investigate the antidepressant treatment received by these subjects. The first 
hypothesis was that previous self-harm and most psychiatric diagnoses, particularly diagnoses 
of affective disorders, has increased the suicide risk. The second hypothesis was that current use 
of antidepressants was low among those who suicide attempt to or successfully commit suicide, 
even when previously diagnosed with an affective disorder.   
Paper III: To explore the main somatic risk factors of suicide, to describe their prescription 
patterns, as well as adherence to antidepressants in suicides and controls, and to assess whether 
antidepressant treatment may play a role in decreasing the risk of suicide in patients with 
somatic disorders. The first hypothesis was that depression underlies several somatic disorders, 
while several somatic disorders, such as cancer, respiratory and cardiovascular disorders, are 
associated with increased risk of suicide. The second hypothesis was that the use and adherence 
to antidepressants was low in subjects with medical illnesses. 
Paper IV: To compare the use of different antidepressant classes and compounds in individuals 
who committed suicide and in controls from the general population in order to assess the extent 
to which adherence and current use of different antidepressant classes can affect the risk of 
committing suicide. The hypothesis was that adherence and current use of antidepressants was 
associated with a lower suicide risk.   
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3 MATERIAL AND METHODS 
3.1 THE REGIONAL “SOCIAL AND HEALTH INFORMATION SYSTEM”  
All data used for this thesis were retrieved from the FVG Regional Social and Health 
Information System (SISSR). This is an unique individual-based health database in Italy, run 
by INSIEL, a major Italian Information Technology company. The SISSR had been 
implemented since the 1990s.  
The SISSR links data using a unique anonymous key from different regional databases. For the 
purpose of this thesis three databases were used: 
1. Death Register (used to identify suicides)  
2. Hospital Discharge Register (used to identify non-fatal self-harm episodes and discharge 
diagnoses according to ICD-9 codes) 
3. Drug Prescription Register (used to retrieve data on antidepressant prescriptions) 
The anonymous key is a unique personal identifier, present in all computerised files. It identifies 
a patient file, which keeps a record for each resident in FVG, including gender, date of birth, 
general practitioner, as well as medical conditions. This enrolment file is updated daily for 
change of general practitioner, births, deaths, and the arrival and departure of the residents from 
the Region. 
It gives information on: 
• Age, gender, residence area. 
• Visits to emergency rooms and other hospitalizations 
• Admission and discharge diagnosis (ICD-9) 
• Medications prescribed by a general practicioner (GP) or other public physicians, 
reimbursed by the National Health System. They include the prescription date, the 
number of packages, the volume (expressed in defined daily doses, DDD), the specific 
antidepressant drug name and its ATC code (118). 
3.2 PAPER I 
Paper I is designed as an ecological study that includes all suicides in FVG between years 1997-
2006, looking at changes in both the rate of suicide and antidepressant use. Cases where the 
cause of death is uncertain were excluded. Data on antidepressants consumption were used for 
the same period, and measured as follows: 
• DDDs per 1000 inhabitants per day 
• Number of individuals treated per year (treatment prevalence) 
• Number of DDDs per individual user (average dosage and duration of treatments) 
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Antidepressants were classified, following ATC codes, as Tricyclics (TCAs), Selective 
Serotonin Reuptake Inhibitors (SSRIs) and “others” (Table 3). SSRI data were available for the 
period 1999-2006, due to the fact that in 1998 these drugs were made free of charge by the 
National Health System (NHS).  
Data on suicides and antidepressants prescriptions were analysed in men and women, as well as 
in age groups 0-59 and ≥60 years.  
 
Table 3: Antidepressant classification in Paper I 
Drug Class ATC code Antidepressant compounds 
Tricyclics (TCAs) N06AA maprotiline and similar older 
Selective Serotonin Reuptake 
Inhibitors (SSRIs) 
N06AB citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline 
Others N06AX venlafaxine, mirtazapine, oxitriptan, mianserin, reboxetin, 
trazodone 
3.2.1 Statistical analysis 
Trends were analysed using curve estimation. Spearman’s Rank Correlation Coefficient was 
used to test correlations. Changes in suicide rates and in the use of antidepressants were 
calculated as Relative Risks (RR) with 95% confidence intervals (95% CI). Odds Ratios (OR) 
with 95 % CI were calculated in order to compare the proportions of subjects taking 
antidepressants (e.g., men compared to women; younger compared to older). The last year of 
the study (2006) was compared to the first year (1997), in all of these calculations.  
3.3 PAPER II, PAPER III AND PAPER IV 
3.3.1 Study design and subjects 
Paper II, III and IV are designed as case-control studies.  
First, we identified subjects who committed suicides in the selected study period, using ICD-9 
codes E95* and E98* for intentional self-harm and events of undetermined intent. Suicides 
were identified as cases. Second, we selected 10 controls in Paper II and III, and  5 controls in 
Paper IV, from the FVG general population. In Paper II, we selected controls as subsequent to 
the respective case in the population register. In Paper III and IV, we selected controls by using 
an incidence density sampling method (119). Controls were then matched by gender and year of 
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birth and had to be alive at the time of suicide of their corresponding case (index date). In Paper 
IV, both cases and controls had to have received at least one prescription of an antidepressant in 
the 730 days prior to death (index date).  
Table 4 shows the study period and the study population with regard to each study.  
 
Table 4: Study period and study population of Papers II, III and IV 
 Paper II Paper III Paper IV 
Years 2002-2008 2003-2013 2005-2014 
Study population 
766 cases 
7660 controls 
1308 cases 
13,080 controls 
876 cases 
4380 controls 
3.3.2 Diagnoses 
We considered, in all the three papers, the main in-patient diagnosis, recorded in the first 
position on the medical record on discharge from public hospitals or private hospitals covered 
by the Regional Health System. Diagnoses were recorded as ICD-9 codes (Table 5). Out-
patients diagnoses were not available. 
In Paper II, non-fatal self-harm episodes were obtained from the Hospital Discharge Register 
and/or emergency room admission forms where “self-harm” was annotated. 
In Papers III and IV, the following diagnoses are not considered and excluded from the data 
analyses:  
• Complications from pregnancy, childbirth, and the puerperium (codes 630–679);  
• Certain conditions originating in the perinatal period (codes 760–779);  
• Injury and poisoning (codes 800–999)  
• External causes of injury and supplemental classification (codes E and V)  
Table 5 summarizes the diagnoses and corresponding ICD-9 codes considered in each paper.  
The psychiatric diagnoses at last discharge from the hospital were considered in Paper II, 
while the time range for diagnoses was the 365 days and the 730 days prior to the index date,  
in Paper III and Paper IV, respectively.  
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Table 5: Diagnoses and corresponding ICD-9 codes, in Papers II, III and IV 
 
Hospital discharge diagnoses 
 
 
ICD-9 codes 
 
Paper 
Psychiatric affective disorders 296, 300.4, 311 Paper II, Paper III,  Paper IV 
Non-affective psychiatric disorders  Paper III, Paper IV (all together) 
Psychosis 295, 297, 298 
Paper II 
Organic  290-294 
Anxiety 300.0-300.3, 300.5-300.9 
Personality 301 
Other 306-310 
Substance Use 303-305 
Somatic disorders  Paper IV (all together) 
Infectious and parasitic diseases 001–139 
Paper III 
Malignant neoplasms 140–208 
Benign neoplasms 210–229 
Carcinoma in situ and other neoplasms  230–239 
Metabolic and immunity disorders 240–279 
Diseases of the blood and blood-forming organs 280–289 
Neurological disorders 320–359 
Diseases of sense organs 360–389 
Heart and vascular diseases 390–459 
Diseases of the respiratory system 460–519 
Diseases of the digestive system 520–579 
Diseases of the genitourinary system 580–629 
Diseases of the skin and subcutaneous tissue 680–709 
Diseases of the musculoskeletal system and 
connective tissue 710–739 
Congenital anomalies 740–759 
Symptoms, signs, and ill-defined conditions 780–799 
3.3.3 Antidepressants 
Data on antidepressant prescriptions  included the prescription date, as well as the number of 
packages and the volume (expressed in DDD). In Paper IV, also the specific antidepressant drug 
name and the corresponding ATC code was included (Table 6). The prescriptions cover more 
than 90% of all antidepressant prescriptions in the region. 
We assessed the use of antidepressants using different parameters in each paper: 
1. Current use of antidepressants prior to death (index date) (Papers II and IV):  
a. Paper II: the last dispensation in the 90 days prior to index date with sufficient 
amount of pills to cover the time to index date, assuming a daily dosage of one 
DDD. 
b. Paper IV: the total number of DDD supplied at the second-to-last prescription 
sufficient to cover the time up to the last prescription, and the total number of 
DDD supplied at the last prescription sufficient to cover the time up to the index 
date. 
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2. Adherence to antidepressants (Papers III and IV): 
It was assesed using the Medical possesion ratio (MPR), defined as the proportion of 
days supplied under a specified time period (120). The total number of DDD 
approximated the number of days of treatment. MPR was calculated as: Total number of DDD during the observation periodobservation period × 100 
Observation period: 365 days prior to the index date in Paper III and 730 days prior to the index date in 
Paper IV 
 
Subjects with an MPR ≥ 80% were defined as adherent to treatment, while subjects 
with an MPR ≤ 79% were defined as non-adherent. 
 
3. Treatment modifications (Paper IV): 
a. The number of switches of antidepressants. A switch is defined as the 
discontinuation of an index antidepressant and the prescription of another 
specific antidepressant. A delay up to 31 days until the prescription of the new 
antidepressant as well as an overlap of the two drugs up to 31 days is allowed 
(121).  
b. The number of combinations of antidepressants. Combination is defined as the 
prescription of the index antidepressant overlapping the prescription of a 
second antidepressant for more than 31 days (121).  
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Table 6: Antidepressant classification in Paper IV 
Drug Class ATC code Antidepressant compounds 
Tricyclics (TCAs) N06AA amitriptiline, clomipramine, nortriptiline, 
trimipramine, imipramine, desipramine, 
dosulepine, maprotiline 
Selective Serotonin Reuptake 
Inhibitors (SSRI) 
N06AB citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine, sertraline 
Serotonergic noradrenergic reuptake 
inhibitors (SNRI) 
N06AX21, N06AX16 venlafaxine, duloxetine 
Others N06AX49, N06AX12, 
N06AX11, N06AF03, 
N06AX03, N06AX18, 
N06AX05 
mirtazapine, mianserin, reboxetine, trazodone, 
bupropion, ademetionin, phenelzine 
3.3.4 Statistical analysis 
In the three papers, continuous variables were summarized using the median as a measure of 
central tendency and the range as a measure of dispersion, whereas dichotomous or categorical 
variables were tabulated into contingency tables. For categorical variables, the chi-square 
statistic (χ2) was used to test the differences between observed and expected frequencies. 
A multivariate logistic regression analysis (Paper II) and a conditional logistic regression 
analysis (Papers III and IV), were used to assess the associations between outcome (suicide) and 
predictors, as follows: 
• Paper II: psychiatric disorders, self-harm, antidepressant prescriptions, time from the 
first prescription of antidepressants 
• Paper III: psychiatric and somatic disorders 
• Paper IV: use of antidepressants 
Crude and adjusted OR and 95% CI were estimated from the logistic regression coefficients and 
their respective standard errors. A P-value (P) < 0.05 was set as the threshold for statistical 
significance.  
In Paper II, subjects who had never been hospitalized for psychiatric disorders and/or self-
harm, as well as subjects who had not been prescribed antidepressants, were used as the 
reference group (OR=1.0). 
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In Paper III, a stratified analysis was performed according to adherence to antidepressants, 
comparing subjects with an MPR 0–79% to subjects with an MPR ≥ 80%. Subjects with no 
discharge diagnosis in the 365 days prior to index date were used as the reference group 
(OR=1.0). 
In Paper IV, stratified analyses were performed according to adherence and current use of 
antidepressants. Subjects who were not prescribed the index antidepressant (i.e. SSRI, SNRI, 
TCA or other), were used as a reference for the conditional regression analyses (OR=1.0). 
Descriptive and inferential analyses were conducted using the statistical software SAS-
Enterprise Guide 4.3 (SAS Institute Inc., Cary,NC, USA), in Paper III and Stata/SE (version 
13.1), in Papers II and IV.  
3.4 ETHICAL CONSIDERATIONS 
Given the characteristics of the SISSR as listed above, the FVG Ethical Committee did not need 
to be consulted for the thesis’ constituting papers, as when developing other epidemiological 
studies in the Region, since epidemiological analyses are provided using only anonymous data. 
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4 MAIN RESULTS 
4.1 PAPER I 
4.1.1 Suicide rates and antidepressant use 
A significant decrease in suicide rates was observed in FVG during years 1997-2006, in both 
genders and age groups (Table 7). In parallel, an increase in the use of antidepressants was 
observed, with all three measures we applied. This increase was greater in the elderly and in 
women (Table 7). SSRI accounted for the most of the increase (71% of individual users in 
2006), whilst the use of TCAs slightly decreased and the use of other antidepressants slightly 
increased (fig. 3). The inverse correlation between the rates of antidepressants use and the rates 
of suicide was confirmed by the Spearman’s rank correlation (r = 0.74, P <0.01), which fitted 
better to a logarithmic curve (log r2 = 0.77).  
 
Table 7: Decrease in suicide rates and increase in antidepressants use with regard to three measures (DDD/1000 
inhabitants./day; number of  users/1000 inhabitants./year; DDD/number of user). Data of year 1997 are compared 
with those of year 2006 
 Suicide rates 
(1997-2006) 
Use of antidepressants 
(1997-2006) 
 N suicides/100,000 inh./ year DDD/1000 inh./day N users/1000inh./year DDD/user 
Genders     
Males 20.5 to 13.5 0.5 to 15.1 6.9 to 32.4 25.6 to 169.1 
Females 7.6 to 5.0 1.1 to 36.9 7.6 to 79.4 25.4 to 169.1 
Age groups     
0-59 10.2 to 7.0 0.5 to 17.5 11.5 to 37.9 46.6 to 168.9 
≥60 23.5 to 14.3 1.8 to 48.1 25.6 to 103.0 25.2 to 170.6 
Total  13.8 to 9.1 (33.8% decrease) 
0.8 to 26.4 
(96.9% increase) 
11.9 to 56.7 
(79% increase) 
25.5 to 169.8 
(85% increase) 
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Fig. 3: Number of people using antidepressants per 1000 inhabitants per year, with regard to different 
antidepressants classes (SSRI, TCA, Other), during years 1997-2006 
 
4.1.2 Use of antidepressants in suicides 
On average, the number of suicide victims who were dispensed antidepressants in the 90 days 
prior to death during years 1997-2006 was 14.8%. The main increase in the number of 
individuals using antidepressants was observed after year 1999, when SSRI became reimbursed 
by the NHS. Significant differences were found when comparing men to women and 0-59 age 
group to ≥60 age group (Table 8).  
 
Table 8: Number and percentages of suicides using antidepressants in the 90 days before death, according to 
genders and age groups. OR with 95% CI was used to compare genders and age groups 
 Suicides using AD in 
the 90 days before 
death 
Total  
N suicides 
 N %  
Genders    
Males 91 9.4 963 
Females 96 25.6 375 
OR (95% CI) 0.32 (0.24-0.43)  
Age groups    
0-59 98 12.3 793 
≥60 89 16.3 545 
OR (95% CI) 0.68 (0.52-0.90)  
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4.2 PAPER II, PAPER III AND PAPER IV 
The proportions of male and female suicides, as well as the proportions of suicides according to 
age groups were similar in the three papers’ population (Table 9). The mean age at which 
people committed suicide was around 56 years (range 12-98 years).  
 
Table 9: Total number and percentages of suicides according to genders and age groups  
 
PAPER II  PAPER III 
 
PAPER IV 
 Suicides  
(N = 766) 
 
 
Suicides  
(N = 1308) 
 Suicides  
(N =1260) 
 N %  N %  N % 
Genders         
Males 552 72.1  957 73.2  928 73.6 
Females 214 27.9  351 26.8  332 26.4 
Age groups         
0-29 66 8.6  98 7.4  95 7.5 
30-59 385 50.3  648 49.5  638 50.6 
≥60 315 41.1  562 43.0  527 41.8 
4.2.1 Previous self-harm, psychiatric and somatic disorders   
The number of cases and controls who previously committed self-harm, as well as those who 
were hospitalised for a psychiatric disorder or a somatic disorder in Paper II and III are 
summarized in Table 10. In Paper II, previous self-harm episodes were found to be associated 
with an increased risk of suicide, as were all psychiatric disorders diagnosed at last hospital 
discharge. Similar findings were observed in Paper III. Somatic disorders led to a three-fold 
increase in suicide risk (Table 10). We also observed that the risk of suicide increased by the 
number of comorbid somatic diagnoses, with a ten-fold increase when subjects were diagnosed 
with four or more somatic disorders. Somatic diagnoses carrying the highest suicide risk were 
respiratory disorders (OR = 2.5). The risk of suicide in somatic disorders was further increased 
by more than four times in subjects older than 60 years, compared to a two times increased risk 
in younger subjects.  
In Paper IV, affective disorders were diagnosed in 6% of suicides who received an 
antidepressant prescription in the 730 days prior to death. The percentage of suicides diagnosed 
with non-affective and somatic disorders was 12.2% and 44.4%, respectively.  
 
 
 
 34 
Table 10: Numbers (N), adjusted odds ratio (OR) and 95% confidence intervals (95% CI) of suicide in subjects 
with previous self-harm, psychiatric and somatic disorders in Papers II and III 
 
PAPER II a  PAPER III b 
 Suicides  
(N=766) 
Controls  
(N=7660)  
Suicide risk, 
adjusted c 
 
 
Suicides  
(N=1308) 
Controls 
(N=13,080) 
 
 
 
Suicide risk, 
adjusted d 
 N N  OR  95% CI  N N  OR  95% CI 
Previous  
self-harm            
1 79 10  53.1 26.2–107.4       
≥1 31 1  98.0 12.4–775.6       
Affective  104 59  21.5 15.0-30.1  106 21  22.0 12.9–37.2 
Non-Affective  
Psychiatric  154 123  15.3 11.6-20.2  213 53  33.1 23.9–45.8 
Somatic        655 3141  2.9  2.5–3.3 
a Psychiatric and somatic diagnoses are referred to last discharge from hospital 
b Psychiatric and somatic diagnoses are referred to last discharge from hospital in the 365 days before the index date 
c Adjusted for age, gender and co-morbid psychiatric diagnoses  
d Adjusted for affective and non-affective disorders  
4.2.2 Antidepressant use 
Although the use of antidepressants was measured in the three studies using different methods, 
in only a minority of cases were suicide victims adherent to antidepressants or currently 
prescribed antidepressants at the time of death (Table 11).  
 
Table 11: Number (N) and percentages (%) of suicides using antidepressants (AD) 
 PAPER II a  PAPER III b  PAPER IV c 
 Suicides  (N=766)  
Suicides  
(N=1308) 
 
 
Suicides 
(N=1260) 
 N %  N %  N % 
AD prescriptions 302 39.4  535 40.9  876 69.5 
Current use of AD d 123 16.1     392 31.1 
Adherence to AD (MPR ≥80%)    151 11.5  334 26.5 
a Data on AD are referred to the 7-years study period 
b Data on AD are referred to the 365 days prior to death 
c Data on AD are referred to the 730 days prior to death 
d Definition of “current use” differs between Paper II and Paper IV 
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Women were more likely to be dispensed antidepressants than men, as were subjects older than 
60 years of age (compared to younger age group). We also observed that women were more 
likely to currently use antidepressants (Paper II) and to adhere to antidepressant treatment 
(Paper III). Furthermore, current use was more likely in elderly compared to younger age group 
(Paper II).   
In Paper II, we found that only one-fifth of the cases diagnosed with a psychiatric disorders 
were currently using antidepressants at the time of death. A similar proportion was found also in 
cases with higher suicide risk, such as subjects who previously committed self-harm or had 
been diagnosed with an affective disorder.  
In Paper III, we compared subjects with somatic disorders that were adherent to antidepressant 
treatment, to those either not prescribed or non-adherent to antidepressant. The risk of suicide 
was not increased in adherent subjects (OR = 1.0; 95% CI =0.7–1.5), while it was increased in 
not prescribed or non-adherent subjects (OR = 2.8; 95% CI = 2.5–3.3).  
In Paper IV, we analysed antidepressant compounds and different antidepressant classes taking 
into account adherence, current use (Table 11), and treatment modifications. SSRI accounted 
for more than 90% of the total prescriptions (N = 827), while SNRI 70% (N =610), TCA 51% 
(N=451) and other antidepressants 52% (N=452). Combinations of antidepressants were found 
in more than half of the users, except users of SSRI (Table 12). When treatment modifications 
were not considered, only one-tenth of SSRI users was adherent to antidepressants (Table 12). 
 
Table 12: Numbers (N) and percentages (%) of treatment modifications and adherence to antidepressants (AD) in 
the 730 days prior to index date, according to different AD classes. Percentages were calculated on the total number 
of suicides in different AD classes for treatment modifications, and on the number of suicides who neither 
combined nor switched AD classes when AD monotherapy was assessed.  
Suicides prescribed AD  
 SSRI   SNRI   TCA  Other 
 N %  N %  N %  N % 
Treatment modifications            
Switches 139 16.8  133 21.8  113 25.1  115 25.4 
Combinations 359 43.4  282 62.5  341 55.9  293 64.2 
AD monotherapy a            
Not adherent to AD (MPR 1-79%) 391  88.5  211  85.4  129  83.2  119  81.0 
Adherent to AD (MPR >80%) 51 11.5  36 14.6  26 16.8  28 19.0 
a Subjects who switched and/or combined antidepressants were not considered 
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The conditional regression analyses showed a higher risk of suicide only in SSRI users (OR = 
1.6, 95% CI 1.1-2.2) among antidepressant classes when adjusted for treatment modifications 
and for psychiatric and somatic diagnoses. The adjusted risk was not significant when the 
analysis was applied to different antidepressant compounds. Moreover, the stratified analyses 
showed a decreasing trend in suicide risk when subjects with an MPR≥ 80% were compared 
to subjects with MPR 1-79%, as well as when subjects currently using antidepressants at the 
time of the index date were compared to subjects that were not. Significantly lower OR of 
suicide was found only in subjects who currently use TCA (OR = 0.7, 95% CI = 0.5-1.0).  
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5 DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
5.1.1 Strengths 
The use of the FVG individual-based register using an unique personal identifier allowed for an 
analysis at the individual level, not based on aggregated data. This also avoided information and 
selection bias, since all studies were based on administrative data with full coverage of the 
regional population. The amount of  information available in the register was quite 
comprehensive, since it included demographic data, in-patients diagnoses, detailed information 
on antidepressant prescriptions, such as prescription date, as well as the number of packages, 
the volume and the specific antidepressant drug name dispensed at each prescription. This 
permitted the analysis of antidepressant use with different parameters at the individual level. 
Moreover, the data, which referred to the 18-year period between 1997 and 2014, were 
exhaustive enough to describe in detail recent findings regarding suicidal behaviour and 
antidepressant use in the FVG Region. We were therefore able provide an overall picture of  
suicide risk factors using different measures that also considered antidepressant use. In 
particular, we used rates (suicide rates, rates of antidepressant use) and ratios (odds ratio) to 
analyse trends in suicide incidence and antidepressant use, as well as the suicide risk related to 
exposure to a variety of different risk factors (i.e. previous self-harm, psychiatric diagnoses, 
somatic diagnoses, qualitative parameters in antidepressant use). Since all data derived from the 
same regional data source, which had a consistently homogeneous population over the time 
period considered, it is less likely that other factors not included in this analysis affected the 
results. 
5.1.2 Limitations 
Paper I was designed as an ecological study. As a consequence, we could not assess the 
influence of other factors on suicide, and causality could not be inferred. Other studies, 
however, had been designed as case-control. The case-control design allowed analysis of causal 
relationships between suicide and the principal suicide risk factors, such as previous self-harm, 
psychiatric disorders and somatic disorders. This also allowed to study the relationship between 
suicide and antidepressant use at the individual level. Nonetheless, several limitations should be 
taken into account: 
5.1.2.1 Statistical power 
Suicide is a rare event. Although the study period of each paper was quite long, the sample size  
still hindered stratified analyses in age and gender subgroups, as in men and women younger 
than 30 years. Further, some stratified analyses we performed, should be interpreted with 
caution, due to small numbers. The odds ratio of suicide in specific diagnostic categories in 
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Paper II may be low powered, since the numbers are small. In Paper III, a similar limitation has 
to be taken into account when analyses were applied to psychiatric and somatic diagnoses in 
specific gender or age group, as when stratified analysis was applied in subjects adherent and 
not adherent to antidepressants. In Paper IV, data limitations prevented further analyses that 
could have yielded interesting and valuable results, such as the effect of using only one class of 
antidepressant or the directions and the type of treatment modifications within different 
antidepressant classes.  
5.1.2.2 Clinical diagnoses 
In Paper II, III and IV, only diagnoses at last discharge from hospital were considered. 
Outpatient diagnoses were not available. This may represent a misclassification of exposure, 
since in-patients were probably more severally ill and could be at a relatively higher suicidal 
risk (35, 122). On the other hand, the unavailability of outpatient diagnoses may have led to an 
underestimation of affective disorders (Paper II, III and IV) or anxiety disorders (Paper II), as an 
indication for antidepressants. Another issue is that diagnoses were clinical and not validated. 
Some degree of inaccuracy in the diagnostic coding, hence, should be considered.  
5.1.2.3 Confounding factors 
The database did not provide information on possible confounders of suicidal behavior, such as 
unemployment, financial loss, socio-economic status, as well as familiar history of suicide. This 
data gap was significant as some of these factors, for instance socio-economic conditions, have 
been observed to underline differences in suicide rates across Italian regions (123). Moreover, 
we had no information on methods of suicide, above all antidepressant poisoning. Nonetheless, 
we could adjust for several confounding factors, such as gender, age, affective and other 
psychiatric diagnoses, somatic diagnoses (Paper II, III and IV) and antidepressant treatment 
modifications (Paper IV).  
5.1.2.4 Antidepressant prescriptions 
Only publicly reimbursed prescriptions of antidepressants were included in the database. We 
calculated, however, that they represent more than 90% of the prescriptions filled in the Region. 
Furthermore, in Paper I, we had no information on the indication of antidepressants. The same 
limitation can be applied to the other papers, whose diagnoses was not available. This may be a 
minor issue, however, since other database studies indicated that antidepressants are prescribed 
for depression in more than half of cases (124). Another study demonstrated that Italian GPs are 
satisfactory in detecting moderate to severe depression (125). An additional limitation is that 
patients’ actual adherence to antidepressant treatment could not be estimated, as in many studies 
based on prescription registers (92, 111, 121, 126). We tried to deal with this calculating 
adherence using MPR (Papers III and IV). The MPR, however, was based on DDD, that only 
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approximates the average recommended dose per day. A possible overestimation of drug 
compliance, hence, should be taken into account. Finally, we did not assess whether 
antidepressants were dispensed before or after hospitalizations for psychiatric or somatic 
disorders (Paper II and III). Nonetheless, in Paper II the current use of antidepressants was 
referred to the last 90 days prior to the index date and in Paper III all prescriptions were referred 
to the 365 days prior to the index date. Due to these limited time periods, it was not possible to 
assess if psychiatric and somatic disorders came before or after hospitalizations.  
5.2 MAIN FINDINGS AND RELATION TO OTHER STUDIES 
5.2.1 Paper I 
Suicide rates in FVG decreased by 30% from 1997 to 2006, while treatment prevalence and 
average dosage and length of antidepressant treatment increased by 80% in the same period. 
The most dramatic increase was observed after SSRI became reimbursed in 1999. In 2006, 70% 
of individual users were prescribed SSRI. The better tolerability of SSRI, thus, may have led to 
higher dosages and longer duration of treatment, as previously observed in Sweden (127). 
Although the inverse correlation between suicide rates and antidepressant use was similar in 
both genders, it was more pronounced in the elderly compared to the young. Antidepressant 
preventive effect on suicide, thus, may be greater among elderly patients (113, 128).  
Although our findings from the region were consistent with international findings (7-9, 63, 64, 
73, 76, 79, 81-87), they conflicted with previous Italian studies, whose conclusions were 
negative towards the hypothesis that antidepressants prevent suicide (88, 89). However, more 
recent data from Italy up to the year 2008 (8) confirmed our hypothesis that antidepressants play 
a preventive role in suicides, whereas although they were based only on antidepressant sales. 
Data from the FVG Region permitted an analysis of the number of users of antidepressants  that 
underestimate the DDD per 1000 inhabitants per day, and, thus, may be considered a more 
reliable estimate for future studies. Further, the analysis could be applied to different genders 
and age groups. This was of great advantage, since drug use, prevalence and incidence of 
depression and suicide rates greatly differ in men and women, as in older and younger subjects 
(79, 87, 113, 115, 129).  
Finally, we observed a low use of antidepressants in suicide in the three months before death, 
consistent with other studies (72, 110, 111). The use of antidepressant increased from 4-6% 
during years 1997-1999 to 15-20% after year 2000, when SSRIs were reimbursed by NHS. Our 
findings therefore indicate that some of the suicide victims that were not treated, would have 
been saved if they had been dispensed, and taken, antidepressants.  
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PAPER I: IMPLICATIONS FOR SUICIDE PREVENTION 
Increased individual use of antidepressants in the population may be an important factor in 
preventing suicide 
The elderly should be considered a main target for suicide prevention with antidepressants 
Suicide prevention strategies should take into account different subgroups of age and gender 
5.2.2 Paper II  
Findings at the individual level during years 2002-2008 indicated that 30% of suicides had been 
hospitalised for a psychiatric disorder, 14% had previously attempted suicide and only 16% had 
been currently using antidepressants at the time of death.  
We found that previous non-lethal self-harm, particularly when repeated, was the strongest 
predictor of completed suicide, consistent with other studies (13-16). Meanwhile, psychiatric 
disorders, particularly affective, psychotic and personality disorders, carried the highest suicide 
risk, as well established in the literature (5, 24, 130-132).  
It was striking that current use of antidepressants was very rare, even among cases diagnosed 
with affective disorders (21%) and cases who previously committed self-harm (20%). An 
improvement in antidepressant treatment among suicide attempters may lead to a decrease in 
suicide risk, as observed in Finland by Tiihonen et al. (71). Nonetheless, in FVG the number of 
suicides treated with antidepressants remained low, despite the drastic increase of antidepressant 
prescriptions in the Region (Paper I). This finding was in contrast with Swedish findings that 
the portion of suicides treated with antidepressants had increased to 29% in 2005 (6).  
However, we found that the risk of suicide decreased by 70% as treatment duration increased 
from less than 20 days to 180 days and more, in line with British findings (69). We agree with 
Jick et al. (69) that the effect of antidepressants is greater in subjects treated for a longer period, 
compared to those recently diagnosed and treated. We also agree that the severity of depression 
may be at its worst when antidepressant treatment starts to be taken.  
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PAPER II: IMPLICATIONS FOR SUICIDE PREVENTION 
Subjects who commit self-harm acts, particularly if repeated, and subjects with psychiatric 
disorders, particularly affective, psychotic and personality disorders, should be considered  
groups at high risk of suicide 
Treatment should be improved particularly in these high risk groups 
Continuous treatment with antidepressant may be an important factor in preventing suicide in 
depressed people 
5.2.3 Paper III 
Somatic disorders increased the risk of suicide by three times in FVG during years 2003-2013. 
This was consistent with other studies (35, 122, 133, 134). The risk was higher among subjects 
aged 60 years and older compared to younger, in contrast with some previous studies (35, 133), 
but consistent with other studies based on the elderly (135). Somatic comorbidities highly 
increased the risk of suicide, as also previously has been observed (35). The highest suicide risk 
among somatic diagnostic categories was observed in respiratory disorders. We interpreted this 
result assuming a possible high burden of chronic obstructive pulmonary disease (COPD) on 
suicidal risk, as indicated by Qin et al. (36). Further, we confirmed malignant neoplasms as an 
important suicidal risk factor (34). However, when stratified analysis by age groups was 
applied, the risk was found to increase only among the elderly. 
In our data set, only 4.7% of suicides with somatic disorders had been hospitalised for affective 
disorders. This may indicate that depression was underdiagnosed, since concomitant depression 
has been found to be common in many somatic disorders (35, 39, 42, 48-51, 136). This 
observation is crucial, since we found that the risk of suicide in subjects who adhere to 
antidepressants in the 365 days prior to death was not significantly increased, while the risk 
increased by more than three times when subjects were not prescribed or did not adhere to 
antidepressants.  
Forty per-cent of suicides were prescribed antidepressants one year prior to death, but only 
11.5% adhered to treatment.  
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PAPER III: IMPLICATIONS FOR SUICIDE PREVENTION 
Somatic disorders should be considered an independent risk factor of suicide, particularly in 
older subjects and subjects with multiple disorders 
Depression is probably underdiagnosed in many somatic disorders. Antidepressants should be 
prescribed in case of somatic disorders with depressive symptoms, since adequate treatment 
with  antidepressants may decrease the risk of suicide 
Primary care and hospital care should be better integrated in order to identify, follow up and 
treat subjects at a higher suicide risk 
5.2.4 Paper IV 
Findings at the individual level during the years 2005-2014 confirmed that SSRI was the most 
frequently prescribed antidepressant class. SSRI was the only class of antidepressants positively 
associated to suicide risk. This association to suicide was in contrast with a previous register 
study (70) and a study based on toxicological screening (65). The finding is not easily 
explainable. It is possible that it might be an effect of confounding bias, since the prescribing of 
SSRIs is more frequent among GPs, who might be less able to monitor treatment and to assess 
and manage suicide risk when compared to psychiatrists (121, 126, 137). In Italy, however, GPs 
are the main antidepressant prescribers. 
Our main finding, however, was that a decreasing trend in suicide risk was observed, among 
subjects who adhere to or currently use antidepressants, compared with those who do not 
currently use or adhere. Previous findings from Denmark indicated a low suicide risk in subjects 
continuously treated with antidepressants, using the number of prescriptions as parameter of 
continuous use (92, 94). However, we did not find other studies using two different qualitative 
parameters on antidepressant use to compare the risk of suicide in a general population.  
Other interesting findings regarded the low adherence to SSRI compared to TCA when these 
classes were analysed separately without taking into account treatment modifications. This 
might be one possible explanation of TCAs lower association to suicide. It might also reflect a 
lower efficiency of SSRI as compared to TCA (92). Nonetheless, a low adherence was found 
for all antidepressant classes, consistent with our previous studies, as well as other Italian (103, 
104, 137) and international findings (108, 121).  
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 PAPER IV: IMPLICATIONS FOR SUICIDE PREVENTION 
An adequate use of antidepressants (i.e. at adequate dosage and for a proper length of time) is 
crucial in achieving a better preventive effect 
Treatment-resistant depression and lower adherence to antidepressants should be considered 
possible precipitating factors of suicide 
Clinicians should monitor treatment in order to ascertain that antidepressants are properly used 
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6 CONCLUSIONS 
Each suicide is a tragic event, and it is of great importance to identify risk factors that can be 
targets for suicide prevention. A better knowledge of suicide epidemiology in a well-defined 
population may contribute to developing appropriate interventions. This is crucial for health 
care, since most suicides suffer from mental and medical disorders. This is also crucial for 
stakeholders, since resources can be allocated on scientific basis. 
The four papers included in this thesis provide a picture of the principal suicide risk factors 
related to health care in FVG, a region with a high rate of suicide. In particular, the possibility 
of preventing suicide through antidepressant medication was particularly analysed. Since the 
regional register of FVG could provide data on the individual level, this research gives unique 
information of great scientific value. 
As previously reported at the international level, as well as in Italy as a whole, FVG has 
experienced a decline in suicide rates in parallel with an increase in antidepressant use. This was 
assessed in our research using data on individual users of antidepressant in different genders and 
age groups.  
The present thesis has highlighted that the risk of suicide was elevated in subjects who 
previously had committed non-lethal self-harm and in subjects diagnosed with affective and 
non-affective psychiatric disorders, and in those suffering from somatic disorders. The elderly 
are identified as a main target for suicide prevention strategies, particularly if they have been 
hospitalised for somatic illnesses. When assessed at the individual level, it was observed that the 
use of antidepressants at a proper dosage and for a proper length of time was associated with a 
decreased risk of suicide. This finding indicates the importance of diagnosing underlying 
depression in somatic disorders. However, a general finding was that antidepressants appear 
underused, also in high-risk populations. 
Notwithstanding the limitations, our research has supported the original a priori hypothesis of 
this research project: that treatment with antidepressant medication lowers the risk of suicide. 
Accordingly, more effort should be given to better identify high-risk groups of suicide and to 
improve antidepressant treatment in these groups. Since suicide victims were generally not 
hospitalised, and antidepressants in Italy mainly are prescribed in primary care settings, it 
appears crucial to involve primary care physicians in such efforts.   
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7 FUTURE PERSPECTIVES 
There is a need or further investigation of suicide - it is a complex phenomenon -, and the 
pathways that lead to suicide should be examined in greater detail. The findings presented in 
this thesis can contribute to a better understanding of risk factors of suicide in relation to health 
care, as well as its prevention. 
Our findings, however, highlighted the need to deepen the research on different genders and age 
subgroups. We demonstrated, for instance, that the elderly are at the highest risk of suicide, but 
research on suicide prevention in the elderly appears to be sparsely investigated area (138). The 
Regional database will enable future projects focused on the elderly. Preliminary data from the 
Region indicates that suicide rates in ageing population are higher in isolated areas than those in 
urban areas. Information available from the Regional database, such as the prevalence of 
psychiatric disorders, somatic disorders and antidepressant prescriptions, can be integrated with  
information on geographical distribution of suicides, deprivation index and distance from the 
closest mental health service. Spatial analysis may provide, thus, a visualization of areas with 
higher suicide rates and a relevant amount of information on suicide victims. As a consequence, 
multidisciplinary prevention strategies may be used, such as training programs for identified 
gatekeepers (e.g. health workers, educators, primary care providers) in order to recognize and 
treat vulnerable persons (139). Further, follow-up and community support may also be used for 
suicide attempters (140). This may enhance the development of prevention strategies that could 
be focused on small communities and would benefit from the collaboration between such 
communities and health care. Such a project may be expanded to other Italian regions that 
experience high suicide rates in the elderly. For instance, a preliminary project design has been 
developed in collaboration with the Italian Region of Sardinia. 
Further research may enhance knowledge on specific somatic disorders and suicide. A first step 
may be developing studies on cancer, since previous Italian studies have indicated  a greater 
risk of suicide among cancer patients (141, 142). The FVG Region has a Cancer Registry (RT-
FVG), where all incident cases of malignant neoplasms in the regional population since 1995 
are registered. The RT-FVG may provide information on the date of  cancer diagnosis and the 
cancer histotype based on Anatomy Pathology Reports, in addition to other information 
available from Regional health database used in this project (SISSR). This may foster a better 
understanding of demographic factors linked to suicide and cancer, the histotypes of cancer 
more closely associated with suicide, the occurrence of suicides after diagnosis of neoplasms 
and discharge from hospital, the comorbidity with psychiatric disorders and the possible role 
of antidepressants in preventing self-harm among cancer patients. Future research may also 
investigate less studied medical illnesses here identified as predictors of suicide, such as 
respiratory and cardiovascular disorders.  
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Finally, a limitation of our studies was that data from regional outpatient services were not 
available in the database. In the current year, a new Informative System will be developed in 
the Region of FVG in order to collect epidemiological data from outpatient mental health 
services. When this system is in place, data will be available that can be linked with data on 
hospitalisations and drug prescriptions. The challenge for the future is to perform suicide 
research along these lines. 
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